High performance plasma amyloid-β biomarkers for Alzheimer's disease. (Q50107488)

25 February 2018

title

High performance plasma amyloid-β biomarkers for Alzheimer's disease. (English)

1 reference

25 February 2018

0 references

1 reference

Taisuke Tomita

11

0 references

Colin L. Masters

19

object named as

Colin L Masters

1 reference

25 February 2018

18

Koichi Tanaka

1 reference

25 February 2018

author name string

Akinori Nakamura

1

1 reference

25 February 2018

Naoki Kaneko

2

1 reference

25 February 2018

Victor L Villemagne

3

1 reference

25 February 2018

Takashi Kato

4

1 reference

25 February 2018

James Doecke

5

1 reference

25 February 2018

Vincent Doré

6

1 reference

25 February 2018

Chris Fowler

7

1 reference

25 February 2018

Qiao-Xin Li

8

1 reference

25 February 2018

Ralph Martins

9

1 reference

25 February 2018

Christopher Rowe

10

1 reference

25 February 2018

Katsumi Matsuzaki

12

1 reference

25 February 2018

Kenji Ishii

13

1 reference

25 February 2018

Kazunari Ishii

14

1 reference

25 February 2018

Yutaka Arahata

15

1 reference

25 February 2018

Shinichi Iwamoto

16

1 reference

25 February 2018

Kengo Ito

17

1 reference

25 February 2018

Katsuhiko Yanagisawa

20

1 reference

25 February 2018

language of work or name

English

0 references

publication date

31 January 2018

1 reference

25 February 2018

published in

Nature

1 reference

25 February 2018

volume

554

1 reference

25 February 2018

issue

7691

1 reference

25 February 2018

page(s)

249-254

1 reference

25 February 2018

https://scigraph.springernature.com/pub.10.1038/nature25456

exact match

0 references

cites work

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

The evolution of preclinical Alzheimer's disease: implications for prevention trials

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

The future of blood-based biomarkers for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Association of plasma and cortical amyloid beta is modulated by APOE ε4 status

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Novel plasma biomarker surrogating cerebral amyloid deposition

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Relationships between biomarkers in aging and dementia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Plasma β-amyloid in Alzheimer's disease and vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

The C-terminus of the beta protein is critical in amyloidogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Clinical Impact of Amyloid Positron Emission Tomography-Is It Worth the Cost?

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Comparison of MR-less PiB SUVR quantification methods

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Age and amyloid effects on human central nervous system amyloid-beta kinetics

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Overcoming synthetic Abeta peptide aging: a new approach to an age-old problem.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Amyloid-beta 42 adsorption following serial tube transfer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Mass++: A Visualization and Analysis Tool for Mass Spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

CSF biomarker variability in the Alzheimer's Association quality control program

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

An analysis of variance test for normality (complete samples)

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Index for rating diagnostic tests

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

1 reference

https://api.crossref.org/works/10.1038%2FNATURE25456

7 January 2021

Identifiers

DOI

10.1038/NATURE25456

1 reference

25 February 2018

1 reference

25 February 2018